Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 55.3 Million USD | 41.62% |
| 2022 | 39.05 Million USD | 44.33% |
| 2021 | 27.05 Million USD | -18.99% |
| 2020 | 33.4 Million USD | 12.92% |
| 2019 | 29.58 Million USD | 16.59% |
| 2018 | 25.37 Million USD | 131.59% |
| 2017 | 10.95 Million USD | 326.26% |
| 2016 | 2.57 Million USD | 68.3% |
| 2015 | 1.52 Million USD | 103.58% |
| 2014 | -42.59 Million USD | -449.16% |
| 2013 | -7.75 Million USD | 83.35% |
| 2012 | -46.58 Million USD | -68.54% |
| 2011 | -27.63 Million USD | -22.41% |
| 2010 | -22.57 Million USD | -15356.08% |
| 2009 | 148 Thousand USD | 105.18% |
| 2008 | -2.85 Million USD | 86.26% |
| 2007 | -20.8 Million USD | 23.23% |
| 2006 | -27.1 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 61.29 Million USD | 5.85% |
| 2024 Q1 | 57.9 Million USD | 4.7% |
| 2023 FY | 55.3 Million USD | 41.62% |
| 2023 Q3 | 56.13 Million USD | 23.68% |
| 2023 Q2 | 45.38 Million USD | 44.86% |
| 2023 Q4 | 55.3 Million USD | -1.46% |
| 2023 Q1 | 31.32 Million USD | -19.78% |
| 2022 Q2 | 35.93 Million USD | 6.79% |
| 2022 Q4 | 39.05 Million USD | 1.12% |
| 2022 Q1 | 33.65 Million USD | 24.38% |
| 2022 FY | 39.05 Million USD | 44.33% |
| 2022 Q3 | 38.62 Million USD | 7.46% |
| 2021 Q4 | 27.05 Million USD | 25.26% |
| 2021 FY | 27.05 Million USD | -18.99% |
| 2021 Q1 | 36.53 Million USD | 9.36% |
| 2021 Q2 | 18.11 Million USD | -50.41% |
| 2021 Q3 | 21.6 Million USD | 19.25% |
| 2020 Q3 | 33.06 Million USD | 8.61% |
| 2020 Q2 | 30.44 Million USD | 3.21% |
| 2020 Q1 | 29.49 Million USD | -0.3% |
| 2020 Q4 | 33.4 Million USD | 1.04% |
| 2020 FY | 33.4 Million USD | 12.92% |
| 2019 Q4 | 29.58 Million USD | -4.53% |
| 2019 Q2 | 26.55 Million USD | 4.2% |
| 2019 Q3 | 30.98 Million USD | 16.71% |
| 2019 FY | 29.58 Million USD | 16.59% |
| 2019 Q1 | 25.48 Million USD | 0.43% |
| 2018 Q3 | 25.67 Million USD | 20.4% |
| 2018 Q1 | 17.5 Million USD | 59.74% |
| 2018 FY | 25.37 Million USD | 131.59% |
| 2018 Q4 | 25.37 Million USD | -1.18% |
| 2018 Q2 | 21.32 Million USD | 21.85% |
| 2017 Q3 | 8.77 Million USD | 24.05% |
| 2017 Q2 | 7.07 Million USD | 0.9% |
| 2017 Q1 | 7.01 Million USD | 172.88% |
| 2017 FY | 10.95 Million USD | 326.26% |
| 2017 Q4 | 10.95 Million USD | 24.8% |
| 2016 Q2 | 17.91 Million USD | 70.6% |
| 2016 FY | 2.57 Million USD | 68.3% |
| 2016 Q3 | 208 Thousand USD | -98.84% |
| 2016 Q4 | 2.57 Million USD | 1135.58% |
| 2016 Q1 | 10.5 Million USD | 587.62% |
| 2015 Q2 | -21.24 Million USD | 20.72% |
| 2015 FY | 1.52 Million USD | 103.58% |
| 2015 Q4 | 1.52 Million USD | 132.67% |
| 2015 Q3 | -4.67 Million USD | 78.0% |
| 2015 Q1 | -26.79 Million USD | 37.1% |
| 2014 Q2 | -32.66 Million USD | 11.41% |
| 2014 Q1 | -36.87 Million USD | -375.33% |
| 2014 FY | -42.59 Million USD | -449.16% |
| 2014 Q4 | -42.59 Million USD | -55.04% |
| 2014 Q3 | -27.47 Million USD | 15.88% |
| 2013 Q1 | -36.8 Million USD | 20.99% |
| 2013 Q4 | -7.75 Million USD | 57.13% |
| 2013 Q2 | -26.91 Million USD | 26.86% |
| 2013 FY | -7.75 Million USD | 83.35% |
| 2013 Q3 | -18.09 Million USD | 32.77% |
| 2012 Q2 | -18.13 Million USD | 20.51% |
| 2012 Q4 | -46.58 Million USD | -241.66% |
| 2012 Q1 | -22.81 Million USD | 17.82% |
| 2012 Q3 | -13.63 Million USD | 24.83% |
| 2012 FY | -46.58 Million USD | -68.54% |
| 2011 Q3 | -32.2 Million USD | 14.88% |
| 2011 FY | -27.63 Million USD | -22.41% |
| 2011 Q1 | -43.43 Million USD | -92.36% |
| 2011 Q4 | -27.76 Million USD | 13.79% |
| 2011 Q2 | -37.83 Million USD | 12.88% |
| 2010 Q4 | -22.57 Million USD | -53.59% |
| 2010 Q2 | -45.62 Million USD | -5616.93% |
| 2010 Q3 | -14.7 Million USD | 67.78% |
| 2010 Q1 | 827 Thousand USD | 458.78% |
| 2010 FY | -22.57 Million USD | -15356.08% |
| 2009 Q3 | 5.1 Million USD | 0.0% |
| 2009 FY | 148 Thousand USD | 105.18% |
| 2009 Q4 | 148 Thousand USD | -97.1% |
| 2008 Q4 | -2.85 Million USD | 0.0% |
| 2008 FY | -2.85 Million USD | 86.26% |
| 2008 Q2 | -30.96 Million USD | -71.82% |
| 2008 Q1 | -18.01 Million USD | 0.0% |
| 2007 FY | -20.8 Million USD | 23.23% |
| 2006 FY | -27.1 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -2903.11% |
| Alpha Teknova, Inc. | 1.97 Million USD | -2701.874% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 41.29% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 26.205% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 87.295% |
| Cosmos Health Inc. | 8.59 Million USD | -543.82% |
| Journey Medical Corporation | -9.7 Million USD | 669.667% |
| Embecta Corp. | 1.31 Billion USD | 95.784% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 87.942% |
| Dynavax Technologies Corporation | 106.63 Million USD | 48.132% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 142.276% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 87.219% |
| PainReform Ltd. | -7.95 Million USD | 795.711% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 453.759% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 453.759% |
| SCYNEXIS, Inc. | -19.35 Million USD | 385.835% |
| Safety Shot Inc | -2.28 Million USD | 2521.187% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 686.538% |
| Procaps Group, S.A. | 242.93 Million USD | 77.233% |
| Theratechnologies Inc. | 24.87 Million USD | -122.383% |
| Harrow Health, Inc. | 116.41 Million USD | 52.491% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 2294.802% |
| Biofrontera Inc. | 4.05 Million USD | -1263.634% |
| DURECT Corporation | -7.65 Million USD | 822.616% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 264.969% |
| Cronos Group Inc. | -663.32 Million USD | 108.338% |
| OptiNose, Inc. | 58.06 Million USD | 4.746% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 91.128% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 479.557% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 1166.5% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -268.407% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 969.687% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -51658.86% |
| Radius Health, Inc. | 359.28 Million USD | 84.606% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -27945.88% |
| ProPhase Labs, Inc. | 19.23 Million USD | -187.603% |
| Phibro Animal Health Corporation | 454.84 Million USD | 87.84% |
| Procaps Group S.A. | 242.93 Million USD | 77.233% |
| Alvotech | 1.06 Billion USD | 94.803% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -1403.779% |
| Viatris Inc. | 17.13 Billion USD | 99.677% |
| Rockwell Medical, Inc. | 4.45 Million USD | -1141.225% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 1234.078% |
| SIGA Technologies, Inc. | -148.68 Million USD | 137.2% |
| Tilray Brands, Inc. | 158.97 Million USD | 65.209% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 54.627% |
| Shineco, Inc. | 29.29 Million USD | -88.83% |
| PetIQ, Inc. | 351.93 Million USD | 84.284% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 2006.268% |
| Incannex Healthcare Limited | -5.48 Million USD | 1108.368% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 68.805% |
| Silver Spike Investment Corp. | -32.61 Million USD | 269.599% |
| Assertio Holdings, Inc. | -32.52 Million USD | 270.03% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 3815.2% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 1192.98% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 1248.92% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 773.393% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -1211.572% |
| Hempacco Co., Inc. | 13.61 Million USD | -306.245% |
| Talphera, Inc. | -5.72 Million USD | 1066.772% |
| Alvotech | 1.06 Billion USD | 94.803% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -674.094% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 157.191% |
| Currenc Group, Inc. | -16.57 Million USD | 433.727% |
| Kamada Ltd. | -46.43 Million USD | 219.12% |
| Indivior PLC | -33.95 Million USD | 262.904% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -21125.832% |
| Flora Growth Corp. | -713 Thousand USD | 7857.223% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 773.393% |
| Evolus, Inc. | 63.7 Million USD | 13.184% |
| HUTCHMED (China) Limited | -197.45 Million USD | 128.011% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 88.456% |
| Akanda Corp. | 3.9 Million USD | -1316.394% |